Home › Compare › KGLDF vs ABBV
KGLDF yields 476.19% · ABBV yields 3.06%● Live data
📍 KGLDF pulled ahead of the other in Year 1
Combined, KGLDF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of KGLDF + ABBV for your $10,000?
King Global Ventures Inc., a junior prospecting and natural-resource company, engages in the acquisition and exploration of mineral properties. The company focuses on gold exploration in Newfoundland. It holds a 100% interest in the York Gold project comprising 77 claims situated in northeastern Quebec; the Boulder Gold property that consists of four contiguous claim blocks of 100 hectares located in Central Newfoundland; and the Golden Nugget property that consists of a 10-kilometer-long contiguous land package of 1850 hectares located in the north of the Davidsville group. The company also holds a 100% interest in the Miss Pickle Island property that consists of 950 hectares located in the Dunnage Coaker Corridor; and the Chapel Island property comprises 54 mining claims situated in northeast-central Newfoundland. The company was formerly known as Rosita Mining Corporation and changed its name to King Global Ventures Inc. in September 2019. King Global Ventures Inc. is headquartered in Toronto, Canada.
Full KGLDF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.